Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 9/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | TERT | O14746 | 1/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16673143 | 0.81 | FDPS (0.55) | FDPSTAAR1ALOX15TERTTBXAS1 | |
| SCHEMBL1706035 | 0.78 | TBXAS1 (0.47) | FDPSTAAR1ALOX15TERTTBXAS1 | |
| SCHEMBL8820621 | 0.77 | FDPS (0.52) | FDPSTAAR1ALOX15TERTTBXAS1 | |
| SCHEMBL3074784 | 0.77 | FDPS (0.61) | FDPSTAAR1ALOX15TERTTBXAS1 | |
| SCHEMBL2622405 | 0.77 | FDPS (0.52) | FDPSTAAR1ALOX15TERTTBXAS1 | |
| SCHEMBL3077019 | 0.77 | FDPS (0.52) | FDPSTAAR1ALOX15TERTTBXAS1 | |
| SCHEMBL4051225 | 0.75 | TBXAS1 (0.49) | FDPSTAAR1ALOX15TERTTBXAS1 | |
| SCHEMBL22648576 | 0.74 | FDPS (0.49) | FDPSTAAR1ALOX15TERTTBXAS1 | |
| SCHEMBL3295265 | 0.73 | — | — | |
| SCHEMBL5897424 | 0.72 | TBXAS1 (0.54) | FDPSTAAR1ALOX15TERTTBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116583521-A | Imidazopyridazine derivatives as IL-17 modulators | UCB生物制药有限责任公司 | 2023-08-11 | — | — | CN | disclosed |
| CN-102119157-A | Tricyclic 2,4-diamino-L,3,5-triazine derivatives useful for the treatment of cancer and myeloproliferative disorders | ASTRAZENECA AB | 2011-07-06 | — | — | CN | disclosed |
| US-7534509-B2 | Ambient-temperature molten salts and process for producing the same | TOYOTA JIDOSHA KABUSHIKI KAISHA (JP) | 2009-05-19 | — | — | US | disclosed |
| US-20060094882-A1 | Ambient-temperature molten salts and process for producing the same | TOYOTA JIDOSHA KABUSHIKI KAISHA | 2006-05-04 | — | — | US | disclosed |
| CN-1093535-C | Imidazole derivative | SHIONOGI & CO (JP) | 2002-10-30 | — | — | CN | disclosed |
| CN-1158609-A | Imidazole derivative | SHIONOGI & CO (JP) | 1997-09-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094882-A1 | Ambient-temperature molten salts and process for producing the same | AFF1, AFF2, AFF4 | FDPS 605/4885TAAR1 258/4885ALOX15 2680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.